![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » LumiraDx Awarded CE Mark for Its Cardiovascular NT-proBNP Test
LumiraDx Awarded CE Mark for Its Cardiovascular NT-proBNP Test
UK-based LumiraDx has received a CE mark for its NT-proBNP test to aid in diagnosing congestive heart failure.
B-type natriuretic peptide (BNP) is a hormone produced by the heart, and N-terminal (NT)-pro hormone BNP (NT-proBNP) is a non-active prohormone that is released from the same molecule that produces BNP.
LumiraDx’s NT-proBNP is a rapid immunofluorescence assay for the quantitative measurement of NT-proBNP in whole blood and plasma specimens.
The company expects to begin marketing the test in Europe later this year.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct